Back to Journals » Open Access Journal of Clinical Trials » Volume 8

Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial

Authors Nacu A, Hoerr R

Received 1 August 2015

Accepted for publication 16 December 2015

Published 18 January 2016 Volume 2016:8 Pages 1—6

DOI https://doi.org/10.2147/OAJCT.S93531

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr RaghunadhaReddy Seelam

Peer reviewer comments 5

Editor who approved publication: Professor Greg Martin

Anatol Nacu,1 Robert Hoerr2

1Clinical Psychiatry Hospital, State University of Medicine and Pharmacy Nicolae Testemiţanu, Chişinău, Republic of Moldova; 2Clinical Research Department, Dr Willmar Schwabe GmbH and Co. KG, Karlsruhe, Germany

Background: In randomized controlled trials, Ginkgo biloba extract EGb 761® has proven to be effective in the treatment of dementia.
Trial registration: Clinical-Trials.ru 390378.
Patients and methods: In pre-specified descriptive analyses of data from a recently published trial, we examined the effects of EGb 761® on specific neuropsychiatric symptoms. In a 24-week, double-blind, multi-center trial, 410 outpatients with mild to moderate dementia and clinically significant neuropsychiatric symptoms were enrolled and randomized to receive 240 mg/day EGb 761® or placebo. The Neuropsychiatric Inventory composite score and the SKT short cognitive performance test were prospectively defined as co-primary outcomes; caregiver distress scores and single item scores were prospectively defined as secondary outcomes.
Results: Post-baseline efficacy data were available for 402 patients included in the full analysis set. Neuropsychiatric Inventory composite and caregiver distress scores improved significantly more under EGb 761® treatment than under placebo (P<0.001). Composite and caregiver distress scores of anxiety, apathy, and disturbances of sleep and nighttime behavior, as well as caregiver distress scores of depression and aberrant motor behavior, were improved most markedly by EGb 761® (P<0.05 vs placebo).
Conclusion: EGb 761® at daily doses of 240 mg alleviated neuropsychiatric symptoms of dementia and reduced related caregiver distress.

Keywords: dementia, neuropsychiatric symptoms, Ginkgo biloba, EGb 761®, randomized controlled trial
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]